Duopharma Biotech Berhad

Informe acción KLSE:DPHARMA

Capitalización de mercado: RM 1.2b

Salud financiera de hoja de balance de Duopharma Biotech Berhad

Salud financiera controles de criterios 4/6

Duopharma Biotech Berhad tiene un patrimonio de accionistas total de MYR696.0M y una deuda total de MYR524.5M, lo que sitúa su ratio deuda-patrimonio en 75.4%. Sus activos y pasivos totales son MYR1.4B y MYR656.9M respectivamente. El BAIT de Duopharma Biotech Berhad es de MYR89.8M, por lo que su ratio de cobertura de intereses es de 4.6. Tiene efectivo e inversiones a corto plazo que ascienden a MYR260.4M.

Información clave

75.4%

Ratio deuda-patrimonio

RM 524.50m

Deuda

Ratio de cobertura de intereses4.6x
EfectivoRM 260.42m
PatrimonioRM 696.05m
Total pasivoRM 656.88m
Activos totalesRM 1.35b

Actualizaciones recientes sobre salud financiera

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17
Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07
Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28
Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27
Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26
We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25
Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 14
A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12
Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Jan 28
Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (MYR725.3M) de DPHARMA superan a sus pasivos a corto plazo (MYR167.6M).

Pasivo a largo plazo: Los activos a corto plazo de DPHARMA (MYR725.3M) superan a sus pasivos a largo plazo (MYR489.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (37.9%) de DPHARMA se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de DPHARMA ha crecido de 52% a 75.4% en los últimos 5 años.

Cobertura de la deuda: La deuda de DPHARMA no está bien cubierta por el flujo de caja operativo (17.9%).

Cobertura de intereses: Los pagos de intereses de la deuda de DPHARMA están bien cubiertos por el BAIT (4.6x cobertura).


Hoja de balance


Descubre empresas con salud financiera